PMID- 36314250
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20230330
IS  - 1097-0045 (Electronic)
IS  - 0270-4137 (Linking)
VI  - 83
IP  - 2
DP  - 2023 Feb
TI  - Effects of apalutamide dose reduction on skin-related adverse events in patients 
      with advanced prostate cancer: A multicenter retrospective study.
PG  - 198-203
LID - 10.1002/pros.24453 [doi]
AB  - BACKGROUND: We aimed to evaluate the effects of apalutamide dose reduction on 
      skin-related adverse events (AEs) and castration-resistant prostate cancer 
      (CRPC)-free survival in patients with advanced prostate cancer (PC). METHODS: We 
      retrospectively evaluated 35 patients with nonmetastatic CRPC and 72 patients 
      with treatment-naive metastatic castration-sensitive PC (mCSPC) who were treated 
      with apalutamide. The primary outcome was the effect of apalutamide dose 
      reduction on skin-related AEs. The secondary outcomes were the effect of 
      apalutamide dose reduction on skin-related AEs in patients with small body size, 
      postskin AE apalutamide discontinuation rate, and CRPC-free survival in patients 
      with mCSPC treated with upfront apalutamide plus androgen deprivation therapy. 
      RESULTS: Of the 107 patients, 65 (60.7%) and 42 (39.3%) were treated with full 
      and reduced doses of apalutamide, respectively. The skin-related AE rate was not 
      significantly different between the groups (55% vs. 43%, p = 0.761). In the group 
      receiving reduced apalutamide dose, the incidence of skin-related AEs was 
      significantly lower in patients with small body sizes (body weight <67 kg and 
      body mass index <24 kg/m(2) ) than in those with other body sizes. The postskin 
      AE apalutamide discontinuation rate was significantly differed between patients 
      receiving the full (50%) and reduced (16.7%) doses. In the 72 patients with 
      mCSPC, CRPC-free survival was not significantly different between the full and 
      reduced dose groups. CONCLUSION: Apalutamide dose reduction was not significantly 
      associated with the incidence of skin-related AEs. However, dose reduction in 
      patients with small body sizes may alleviate skin-related AEs without sacrificing 
      oncological outcomes.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Oishi, Takuya
AU  - Oishi T
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Hatakeyama, Shingo
AU  - Hatakeyama S
AUID- ORCID: 0000-0002-0026-4079
AD  - Department of Advanced Blood Purification Therapy, Hirosaki University Graduate 
      School of Medicine, Hirosaki, Japan.
FAU - Tabata, Ryuji
AU  - Tabata R
AD  - Department of Urology, Ageo Central General Hospital, Ageo, Japan.
FAU - Fujimori, Daiji
AU  - Fujimori D
AD  - Department of Urology, Ageo Central General Hospital, Ageo, Japan.
FAU - Kawashima, Yohei
AU  - Kawashima Y
AD  - Department of Urology, Ageo Central General Hospital, Ageo, Japan.
FAU - Tanaka, Ryuma
AU  - Tanaka R
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Ishii, Noritaka
AU  - Ishii N
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Miura, Hikari
AU  - Miura H
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Tanaka, Toshikazu
AU  - Tanaka T
AD  - Department of Urology, Aomori Prefectural Central Hospital, Aomori, Japan.
FAU - Okamoto, Teppei
AU  - Okamoto T
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Yamamoto, Hayato
AU  - Yamamoto H
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Yoneyama, Takahiro
AU  - Yoneyama T
AD  - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University 
      Graduate School of Medicine, Hirosaki, Japan.
FAU - Hashimoto, Yasuhiro
AU  - Hashimoto Y
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
FAU - Sato, Satoshi
AU  - Sato S
AD  - Department of Urology, Ageo Central General Hospital, Ageo, Japan.
FAU - Ohyama, Chikara
AU  - Ohyama C
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, 
      Japan.
AD  - Department of Advanced Blood Purification Therapy, Hirosaki University Graduate 
      School of Medicine, Hirosaki, Japan.
AD  - Department of Advanced Transplant and Regenerative Medicine, Hirosaki University 
      Graduate School of Medicine, Hirosaki, Japan.
LA  - eng
GR  - 19H05556/Japan Society for the Promotion of Science/
GR  - 20K09517/Japan Society for the Promotion of Science/
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20221031
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (apalutamide)
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Androgen Antagonists)
SB  - IM
MH  - Male
MH  - Humans
MH  - Retrospective Studies
MH  - *Androgen Receptor Antagonists/therapeutic use
MH  - Androgen Antagonists/therapeutic use
MH  - *Prostatic Neoplasms, Castration-Resistant/pathology
OTO - NOTNLM
OT  - adverse events
OT  - castration-resistant
OT  - castration-sensitive
OT  - prostate cancer
OT  - skin
EDAT- 2022/11/01 06:00
MHDA- 2022/12/21 06:00
CRDT- 2022/10/31 05:23
PHST- 2022/09/30 00:00 [revised]
PHST- 2022/07/22 00:00 [received]
PHST- 2022/10/14 00:00 [accepted]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/10/31 05:23 [entrez]
AID - 10.1002/pros.24453 [doi]
PST - ppublish
SO  - Prostate. 2023 Feb;83(2):198-203. doi: 10.1002/pros.24453. Epub 2022 Oct 31.